First trachea transplant without immunosuppression

November 19, 2008

* Tissue engineering has made possible this doubly innovative operation - the first trachea transplant and the first tissue transplant to be performed without the need for immunosuppression.
* Professor Paolo Macchiarini, Head of the thoracic surgery department of Hospital Clínic has led the basic research and the international team formed by the universities of Bristol, Padua and Milan, who contributed to this success.
* The transplanted tissue is a hybrid from a donor that was repopulated with stem and epithelial cells from the recipient. Five months later, Claudia Castillo, who required the operation to save a lung following tuberculosis, is in perfect health.

After 4 years of going from consultation to consultation, Claudia Castillo finally found a solution to her respiratory problems. The young Colombian woman suffered from a cough that took a long time to be diagnosed as tuberculosis. She arrived at Hospital Clínic of Barcelona with complications and there, she met Professor Paolo Macchiarini Head of the Thoracic Surgery Department, who had led the international team that made possible the first trachea transplant and the first tissue transplant without immunosuppression. She underwent an operation on the upper part of the trachea but nothing could be done to repair the blockage in the left lung. The infection had led to a severe collapse just before the branch of the trachea and this obstruction prevented air from reaching the lung. The only treatment option at the time involved removing the affected lung. As the young mother of two children, removing the lung would have considerably reduced quality of life for Claudia Castillo. In March 2008, her situation worsened to the point where she was unable to carry out domestic chores or look after her children, so intervention became urgent. In June, after obtaining authorization from the ethics committee of Hospital Clínic of Barcelona and from the Catalan Transplant Organization (OCATT), the first trachea transplant and the first tissue transplant of any kind without immunosuppression took place.

The study, which will be published online on Wednesday by the journal The Lancet, with Professor Paolo Macchiarini as the principal author, together with his colleagues Dr. Philip Jungebluth, Dr. Tetsuhiko Go and Dr. Jaume Martorell, presents the details of this transplant - the first treatment alternative for treating the collapsed trachea that the patient was suffering from. The technique consists of depleting the trachea to be transplanted of the donor's cells and repopulating it with cells from the recipient before the operation. Thus, thanks to tissue bioengineering, the donor trachea becomes a hybrid that the recipient's body identifies as its own, thereby making immunosuppression unnecessary. The transplant and most of the processes involved were carried out at Hospital Clínic of Barcelona, but this would have been impossible without the collaboration of the University of Bristol (UK), the University of Padua (Italy) and the University of Milan (Italy). The prior basic research was led by Professor Paolo Macchiarini.

The process of preparing the trachea requires many cycles of washing to eliminate all the donor cells - many more than those suggested by the basic research. The tissue was a 7-cm segment of trachea from a 51-year-old donor who had died from brain hemorrhage. The team of Dr. Maria T. Conconi at the University of Padua (Italy) confirmed that, after 25 washing cycles, the trachea treated at Hospital Clínic was free from donor antigens - the molecules that would cause the tissue to be rejected by the recipient. Meanwhile, at the University of Bristol, the teams of Professor Martin Birchall and Professor Anthony Hollander cultivated the recipient's cells that would later be introduced into the trachea. These cells were epithelial cells taken from the trachea and cartilage cells (chondrocytes), differentiated from stem cells taken from the patient's bone marrow. This technique was initially designed to treat cases of osteoarthritis. Back at Hospital Clínic, the team of Professor Paolo Macchiarini introduced these cells into the trachea using a bioreactor designed by the team of Dr. Sandra Mantero at the University of Milan. The epithelial cells were inserted into the inner surface of the trachea and the chondrocytes covered the outer surface. The donor tissue thus became a hybrid very similar to new tissue from the patient themselves.

The operation was performed 4 days later at Hospital Clínic, where the thoracic surgery team extracted the damaged section of trachea and replaced it with the new trachea. This pioneering operation was not without question marks but if anything had gone wrong, it would have been changed to a lung-resection operation - the classical treatment choice. Thanks to the skill of the surgeons and the huge international effort, the operation was a success. Five months later, the lung that had been so long out of use was providing normal respiration.

This innovation in biomedicine and surgery may become an alternative for diseases of the upper airways, such as congenital deformities or primary tumors, which cannot currently be treated using conventional surgical techniques. The clinical application of stem-cell cultures and the prevention of the problems deriving from immunosuppression are a milestone in the history of transplantation. There are already some cases being studied that may benefit from the new technique and research continues into improving the process. If all goes well, Claudia Castillo will be just the first patient to benefit from a new advance led by researchers from Hospital Clínic of Barcelona.

IDIBAPS - Institut d'Investigacions Biomèdiques August Pi i Sunyer

---

---

	Immunosuppression by Progesterone in Pregnancy by Julia Szekeres-Bartho (Author) Immunosuppression by Progesterone in Pregnancy describes a newly discovered feto-protective mechanism resulting from the interaction of the immune and endocrine systems. As a response to antigenic stimulation by the fetus, lymphocytes of pregnant women develop non-classical progesterone receptors. Receptor binding of progesterone in the lymphocytes triggers the production of a mediator protein. Through an immunological pathway, this protein prevents abortion in murine models, and its serum concentration correlates with pregnancy outcome in humans. The regulation of these unusual receptors, as well as diagnostic and therapeutic implications of the mediator protein, are discussed. Immunologists, reproductive biologists, obstetricians, gynecologists, and other researchers studying this...
	Immunosuppression in Inflammatory Bowel Diseases: Standards, New Developments, Future Trends (Falk Symposium) by K. Fellermann (Editor), D.P. Jewell (Editor), W.J. Sandborn (Editor), J. Schölmerich (Editor), E.-F. Stange (Editor) The aetiology of the chronic inflammatory bowel diseases - Crohn's disease and ulcerative colitis - is still enigmatic. The therapeutic approach has therefore traditionally focused on anti-inflammatory principles, including corticosteroids and aminosalicylates. Since a significant proportion of patients is steroid-dependent or refractory and because of the problematic side-effects of long-term systemic steroids, active immunosuppression has gained acceptance in the field. The classical immunosuppressants azathioprine and 6-mercaptopurine have long been evidence-based in IBD, but underused. Recently, methotrexate and cyclosporine have also been proven to be effective in certain situations. Newer drugs like tacrolimus, mycophenolate and others may be similarly useful but their...
	Virus-Induced Immunosuppression (Infectious Agents and Pathogenesis) by Steven Specter (Editor), Mauro Bendinelli (Editor), Herman Friedman (Editor)
	The Molecular Biology of Immunosuppression (Molecular Medical Science Series) by Angus W. Thompson (Editor) This text is part of the Molecular Medical Science series and covers such topics as self non-self discrimination by the immune system; the use of cytokines and their receptors to monitor and manipulate the immune response; and tolerance to alloantigens.
	Therapeutic Immunosuppression (Immunology and Medicine, Volume 29) by A.W. Thomson (Editor) Therapeutic immunosuppression has very broad applications in clinical medicine, ranging from prevention and treatment of organ and bone marrow transplant rejection, management of various autoimmune disorders (e.g., rheumatoid arthritis), skin disease, and asthma. Whereas traditionally only a small repertoire of immunosuppressive agents was available for clinical use, recent discoveries have significantly increased the number of approved agents, resulting in numerous trials to further evaluate their potential. In addition, products of the biotechnology industry - monoclonal antibodies, cytokines, cytokine antagonists, and other products of genetic engineering that target key molecular pathways in disease pathogenesis - have either already made, or are on the verge of making an ...
	Clinical immunosuppression by Grune & Stratton (Publisher)
	Viral Mechanisms of Immunosuppression (Progress in leukocyte biology) by Norbert Gilmore (Author), Mark A. Wainberg (Author)
	Growth Immunosuppression and Renal Disorders in Neonates and Children: Current Concepts in Diagnosis and Management by Jose Strauss (Author), Louise Strauss (Author), Jose Strauss (Editor), Louise Strauss (Editor)
	Immunosuppression & Human Malignancy (Contemporary Immunology) by David Naor (Author), Benjamin Y. Klein (Author), Nora Tarcic (Author), Jonathan S. Duke-Cohan (Author) This original and incisive new book by Naor and his colleagues, Immunosuppression and Human Malignancy, offers a state-of-the-art critical analysis of the huge body of recent research on the immunosuppressive states associated with malignancy. Maximum attention is paid to the role of suppressor macrophages and lymphocytes in malignancy-related immunodepression. The central question posed is whether immunosuppression induces carcinogenesis and/or tumor progression, or whether it is instead the result of these processes and/or the therapy protocols. Sources of experimental artifacts are also evaluated. Encyclopedically presented, each chapter of Immunosuppression and Human Malignancy can be read independently, and each chapter features a detailed table summarizing that chapter's major...
	Immunosuppression: New Research by Charles B. Taylor (Editor) Immunosuppression involves an act that reduces the activation or efficacy of the immune system. Some portions of the immune system itself have immuno-suppressive effects on other parts of the immune system, and immunosuppression may occur as an adverse reaction to treatment of other conditions. Deliberately induced immunosuppression is generally done to prevent the body from rejecting an organ transplant, treating graft-versus-host disease after a bone marrow transplant, or for the treatment of auto-immune diseases such as rheumatoid arthritis or Crohn's disease. This is typically done using drugs, but may involve surgery (splenectomy), plasmapharesis, or radiation.A person who is undergoing immunosuppression, or whose immune system is weak for other reasons (for example, chemotherapy and...